Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SCN4A | P35499 | 2/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154124 | 0.87 | NPC1 (0.45) | NPC1RAB9ASCN4ASCN9ASMN1; SMN2 | |
| SCHEMBL533470 | 0.77 | CYP1A2 (0.49) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL212072 | 0.74 | EPHX2 (0.49) | SCN4AGAAPKMDYRK1AACP1 | |
| SCHEMBL15281308 | 0.71 | NPC1 (0.54) | NPC1RAB9ASCN4ASCN9ASMN1; SMN2 | |
| SCHEMBL29414924 | 0.71 | NPC1 (0.54) | NPC1RAB9ASCN4ASCN9ASMN1; SMN2 | |
| SCHEMBL8014001 | 0.71 | CA1 (0.49) | LMNATP53CYP3A4GAAHSD17B10 | |
| SCHEMBL4996297 | 0.71 | NPC1 (0.34) | NPC1RAB9ASCN4ASCN9ASMN1; SMN2 | |
| SCHEMBL206753 | 0.71 | GFER (0.44) | NPC1RAB9ASMN1; SMN2LMNAPKM | |
| SCHEMBL3091070 | 0.70 | NPC1 (0.69) | NPC1RAB9ASCN4ASCN9ASMN1; SMN2 | |
| SCHEMBL10220007 | 0.70 | NPC1 (0.64) | NPC1RAB9ASCN4ASCN9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567438-B | Riluzole prodrugs and uses thereof | 拜尔哈文制药股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2017-11-23 | — | — | US | disclosed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150224083-A1 | Cancer Therapy With Cantharidin And Cantharidin Analogs | STEMLINE THERAPEUTICS INC (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-02-12 | — | — | US | disclosed |
| US-20080267947-A1 | Cancer therapy with cantharidin and cantharidin analogs | STEMLINE THERAPEUTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008030617-A2 | CANCER THERAPY WITH CANTHARIDIN AND CANTHARIDIN ANALOGS | STEMLINE THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224083-A1 | Cancer Therapy With Cantharidin And Cantharidin Analogs | ASAH2, TYR, CD47 | NPC1 2616/4885RAB9A 578/4885SCN4A 4059/4885 |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | NPC1 3132/4885RAB9A 1164/4885SCN4A 4378/4885 |
| US-20080267947-A1 | Cancer therapy with cantharidin and cantharidin analogs | ASAH2, TYR, CD47 | NPC1 2616/4885RAB9A 578/4885SCN4A 4059/4885 |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | NPC1 3132/4885RAB9A 1164/4885SCN4A 4378/4885 |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | NPC1 3132/4885RAB9A 1164/4885SCN4A 4378/4885 |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | NPC1 3132/4885RAB9A 1164/4885SCN4A 4378/4885 |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | NPC1 3132/4885RAB9A 1164/4885SCN4A 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.